Gemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa study

Strumberg, D.Schultheis, B.Ebert, M. P.Siveke, J.Kerkhoff, A.Berdel, W.Hofheinz, R.Behringer, D. M.Schmidt, W. E.Goker, E.De Dosso, S.Kneba, M.Yalcin, S.Overkamp, F.Schlegel, F.Dommach, M.Rohrberg, R.Steinmetz, T.Reuter, D.Bach, F.2019-10-272019-10-2720142296-52702296-5262https://hdl.handle.net/11454/48369eninfo:eu-repo/semantics/closedAccessGemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa studyConference Object375757WOS:000332306700187N/A